March 13, 2025

FDA Chief Counsel Resigns Two Days In

U.S. FDA's chief counsel resigns amidst controversy surrounding her appointment and connections to mifepristone during the Biden administration.

Reuters

March 10, 2025

AI Methods Strengthen Real-World Data Reliability

Researchers assessed the impact of AI-driven methods on real-world data reliability, showing improvements in accuracy, completeness, and traceability

Conexiant

March 05, 2025

FDA Monthly Round-Up: Key February Updates

February's FDA approvals feature advancements in cardiology, neurology, infectious diseases, and rare disorders, including the first trials for genetically modified pig kidney transplants and novel treatments for Parkinson’s disease and spinal muscular atrophy.

Conexiant

March 03, 2025

More States Fast Track Foreign-Trained Physicians

Since 2023, nine states have waived U.S. residency requirements for some foreign-trained physicians, with more states considering similar changes.

KFF Health News

March 03, 2025

FDA Approves New Hormone-Free Copper IUD

The FDA has approved Miudella, a hormone-free copper IUD, for pregnancy prevention for up to three years, marking the first approval of a new copper IUD in the U.S. in over 40 years.

Conexiant

February 25, 2025

FDA Delays Update on 'Healthy' Label

The finalization of new criteria for the "healthy" nutrient content claim on food labels has been delayed, allowing more time for regulatory review of standards that could significantly influence labeling practices and help reduce diet-related chronic diseases.

Conexiant

February 24, 2025

Game-Changer for Pfizer? Former FDA Drug Chief Takes Reins

Before leadership at the FDA, Dr. Patrizia Cavazzoni spent nearly 2 decades in the pharmaceutical industry.

Conexiant

February 21, 2025

FDA Approves First Cerebrotendinous Xanthomatosis Treatment

The FDA has approved Ctexli (chenodiol) as the first treatment for cerebrotendinous xanthomatosis, a rare lipid storage disorder.

Conexiant

February 21, 2025

FDA Ends Semaglutide Shortage, Updates Policy

FDA declares resolution of nationwide semaglutide injection shortage and outlines 60 to 90 day transition periods for compounding facilities while other GLP-1 medications remain in limited supply.

Conexiant